243 related articles for article (PubMed ID: 26241306)
1. Hepatitis C virus: why do we need a vaccine to prevent a curable persistent infection?
Walker CM; Grakoui A
Curr Opin Immunol; 2015 Aug; 35():137-43. PubMed ID: 26241306
[TBL] [Abstract][Full Text] [Related]
2. Chimeric hepatitis B virus/hepatitis C virus envelope proteins elicit broadly neutralizing antibodies and constitute a potential bivalent prophylactic vaccine.
Beaumont E; Patient R; Hourioux C; Dimier-Poisson I; Roingeard P
Hepatology; 2013 Apr; 57(4):1303-13. PubMed ID: 23150224
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis C Virus Envelope Glycoproteins: A Balancing Act of Order and Disorder.
Yost SA; Wang Y; Marcotrigiano J
Front Immunol; 2018; 9():1917. PubMed ID: 30197646
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis C Virus Vaccine Research: Time to Put Up or Shut Up.
Hartlage AS; Kapoor A
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452460
[TBL] [Abstract][Full Text] [Related]
5. A Multiantigenic DNA Vaccine That Induces Broad Hepatitis C Virus-Specific T-Cell Responses in Mice.
Gummow J; Li Y; Yu W; Garrod T; Wijesundara D; Brennan AJ; Mullick R; Voskoboinik I; Grubor-Bauk B; Gowans EJ
J Virol; 2015 Aug; 89(15):7991-8002. PubMed ID: 26018154
[TBL] [Abstract][Full Text] [Related]
6. Vaccine-induced cross-genotype reactive neutralizing antibodies against hepatitis C virus.
Meunier JC; Gottwein JM; Houghton M; Russell RS; Emerson SU; Bukh J; Purcell RH
J Infect Dis; 2011 Oct; 204(8):1186-90. PubMed ID: 21917891
[TBL] [Abstract][Full Text] [Related]
7. A novel combined vaccine candidate containing epitopes of HCV NS3, core and E1 proteins induces multi-specific immune responses in BALB/c mice.
Zeng R; Li G; Ling S; Zhang H; Yao Z; Xiu B; He F; Huang R; Wei L
Antiviral Res; 2009 Oct; 84(1):23-30. PubMed ID: 19646486
[TBL] [Abstract][Full Text] [Related]
8. N-glycosylation-mutated HCV envelope glycoprotein complex enhances antigen-presenting activity and cellular and neutralizing antibody responses.
Ren Y; Min YQ; Liu M; Chi L; Zhao P; Zhang XL
Biochim Biophys Acta; 2016 Aug; 1860(8):1764-75. PubMed ID: 26278021
[TBL] [Abstract][Full Text] [Related]
9. Antibody Responses in Hepatitis C Infection.
Law M
Cold Spring Harb Perspect Med; 2021 Mar; 11(3):. PubMed ID: 32341067
[TBL] [Abstract][Full Text] [Related]
10. Antibodies Targeting Novel Neutralizing Epitopes of Hepatitis C Virus Glycoprotein Preclude Genotype 2 Virus Infection.
Deng K; Liu R; Rao H; Jiang D; Wang J; Xie X; Wei L
PLoS One; 2015; 10(9):e0138756. PubMed ID: 26406225
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C virus vaccine design: focus on the humoral immune response.
Sepulveda-Crespo D; Resino S; Martinez I
J Biomed Sci; 2020 Jul; 27(1):78. PubMed ID: 32631318
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a Phase I clinical trial.
Alvarez-Lajonchere L; Shoukry NH; Grá B; Amador-Cañizares Y; Helle F; Bédard N; Guerra I; Drouin C; Dubuisson J; González-Horta EE; Martínez G; Marante J; Cinza Z; Castellanos M; Dueñas-Carrera S
J Viral Hepat; 2009 Mar; 16(3):156-67. PubMed ID: 19017255
[TBL] [Abstract][Full Text] [Related]
13. Neutralizing antibodies induced by cell culture-derived hepatitis C virus protect against infection in mice.
Akazawa D; Moriyama M; Yokokawa H; Omi N; Watanabe N; Date T; Morikawa K; Aizaki H; Ishii K; Kato T; Mochizuki H; Nakamura N; Wakita T
Gastroenterology; 2013 Aug; 145(2):447-55.e1-4. PubMed ID: 23673355
[TBL] [Abstract][Full Text] [Related]
14. A novel hepatitis C virus vaccine approach using recombinant Bacillus Calmette-Guerin expressing multi-epitope antigen.
Wei SH; Yin W; An QX; Lei YF; Hu XB; Yang J; Lu X; Zhang H; Xu ZK
Arch Virol; 2008; 153(6):1021-9. PubMed ID: 18421415
[TBL] [Abstract][Full Text] [Related]
15. Evolution of the Humoral Response during HCV Infection: Theories on the Origin of Broadly Neutralizing Antibodies and Implications for Vaccine Design.
Murira A; Lapierre P; Lamarre A
Adv Immunol; 2016; 129():55-107. PubMed ID: 26791858
[TBL] [Abstract][Full Text] [Related]
16. Will there be a vaccine to prevent HCV infection?
Honegger JR; Zhou Y; Walker CM
Semin Liver Dis; 2014 Feb; 34(1):79-88. PubMed ID: 24782261
[TBL] [Abstract][Full Text] [Related]
17. Advances in DNA immunization against hepatitis C virus infection.
Alvarez-Lajonchere L; Dueñas-Carrera S
Hum Vaccin; 2009 Aug; 5(8):568-71. PubMed ID: 19736511
[TBL] [Abstract][Full Text] [Related]
18. Recombinant adenoviral vector expressing HCV NS4 induces protective immune responses in a mouse model of Vaccinia-HCV virus infection: a dose and route conundrum.
Singh S; Vedi S; Li W; Samrat SK; Kumar R; Agrawal B
Vaccine; 2014 May; 32(23):2712-21. PubMed ID: 24631092
[TBL] [Abstract][Full Text] [Related]
19. Current Hepatitis C Vaccine Candidates Based on the Induction of Neutralizing Antibodies.
Gomez-Escobar E; Roingeard P; Beaumont E
Viruses; 2023 May; 15(5):. PubMed ID: 37243237
[TBL] [Abstract][Full Text] [Related]
20. Neutralizing antibodies and broad, functional T cell immune response following immunization with hepatitis C virus proteins-based vaccine formulation.
Martinez-Donato G; Amador-Cañizares Y; Alvarez-Lajonchere L; Guerra I; Pérez A; Dubuisson J; Wychowsk C; Musacchio A; Aguilar D; Dueñas-Carrera S
Vaccine; 2014 Mar; 32(15):1720-6. PubMed ID: 24486345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
